⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL43356 | 0.74 | GPR35 (0.38) | — | |
| SCHEMBL25433762 | 0.73 | — | — | |
| SCHEMBL27720136 | 0.73 | — | — | |
| SCHEMBL25690531 | 0.73 | — | — | |
| SCHEMBL266568 | 0.73 | — | — | |
| SCHEMBL3585568 | 0.73 | — | — | |
| SCHEMBL21544010 | 0.73 | — | — | |
| SCHEMBL4111984 | 0.73 | — | — | |
| SCHEMBL10566808 | 0.71 | MAPT (0.43) | — | |
| SCHEMBL31668869 | 0.71 | LMNA (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665734-A1 | CYCLIN-DEPENDENT KINASE (CDK2) INHIBITORS | Novartis AG (CH) | 2025-12-24 | — | — | EP | disclosed |
| EP-4618977-A1 | LRRK2 INHIBITORS AND USES THEREOF | Neuron23, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| WO-2025092989-A1 | SUBSTITUTED QUINAZOLINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMBINATION THEREOF, AND USE THEREOF | 泰州红云制药有限公司 | 2025-05-08 | — | — | WO | disclosed |
| US-20240360137-A1 | CYCLIN-DEPENDENT KINASE (CDK2) INHIBITORS | NOVARTIS AG (CH) | 2024-10-31 | — | — | US | disclosed |
| WO-2024218296-A1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS | H. LUNDBECK A/S (DK) | 2024-10-24 | — | — | WO | disclosed |
| EP-4422750-A1 | LRRK2 INHIBITORS | H. Lundbeck A/S (DK) | 2024-09-04 | — | — | EP | disclosed |
| WO-2024171094-A1 | CYCLIN-DEPENDENT KINASE (CDK2) INHIBITORS | NOVARTIS AG (CH) | 2024-08-22 | — | — | WO | disclosed |
| US-20240228493-A1 | LRRK2 INHIBITORS AND USES THEREOF | NEURON23, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228493-A1 | LRRK2 INHIBITORS AND USES THEREOF | NEURON23, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240217977-A1 | DIAZEPANONE-FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | LENGO THERAPEUTICS, INC. | 2024-07-04 | — | — | US | disclosed |
| US-9212173-B2 | Pyrazole aminopyrimidine derivatives as LRRK2 modulators | GENENTECH, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-9044017-B2 | Processes for the preparation of pesticidal compounds | DOW AGROSCIENCES LLC (US) | 2015-06-02 | — | — | US | disclosed |
| US-9044017-B2 | Processes for the preparation of pesticidal compounds | DOW AGROSCIENCES LLC (US) | 2015-06-02 | — | — | US | disclosed |
| EP-2844652-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2015-03-11 | — | — | EP | disclosed |
| US-20150051238-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH, INC. (CA) | 2015-02-19 | — | — | US | disclosed |
| CN-104271569-A | Pyrazolylaminopyrimidine derivatives as LRRK2 modulators | HOFFMANN LA ROCHE | 2015-01-07 | — | — | CN | disclosed |
| WO-2013164321-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-11-07 | — | — | WO | disclosed |
| EP-1090060-A1 | MODIFIED POLYCONDENSATES OF ASPARAGINIC ACID, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE IN FERTILIZERS | BASF AKTIENGESELLSCHAFT (DE) | 2001-04-11 | — | — | EP | disclosed |
| WO-1999058594-A1 | MODIFIED POLYCONDENSATES OF ASPARAGINIC ACID, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE IN FERTILIZERS | BASF AKTIENGESELLSCHAFT (DE) | 1999-11-18 | — | — | WO | disclosed |
| EP-0201188-A2 | 5-Substituted pyrazolo[4,3-d] pyrimidine-7-ones, process for preparing the compounds and pharmaceutical compositions comprising the compounds | WARNER-LAMBERT COMPANY (US) | 1986-12-17 | — | — | EP | disclosed |